论文部分内容阅读
本研究旨在评价自体细胞因子诱导的杀伤细胞(cytokine-induced killer cells,CIK)治疗老年骨髓增生异常综合征(myelodysplastic syndromes,MDS)的安全性和有效性。采集6例老年MDS患者外周血单个核细胞,在体外经细胞刺激因子培养,诱导成CIK细胞,回输至患者体内,28天为1个疗程。观察CIK细胞回输后患者体内效应细胞的比例变化、不良反应以及对感染的发生、血红蛋白水平和对输血依赖程度的影响。结果表明,经CIK细胞治疗后CD3+、CD3+CD8+、CD3+CD56+细胞比例明显升高(p<0.05),所有患者未出现严重不良反应。CIK细胞治疗有效地减少了MDS患者感染的发生,缩短了高热时间。在疾病稳定期,CIK细胞输注可减少红细胞的输注量,稳定血红蛋白水平,但不能改变MDS向高危亚型转化的自然病程。结论 :自体CIK细胞输注治疗老年人MDS安全有效。
This study was designed to evaluate the safety and efficacy of cytokine-induced killer cells (CIK) in the treatment of myelodysplastic syndromes (MDS). Peripheral blood mononuclear cells from 6 elderly patients with MDS were collected and cultured in vitro and induced into CIK cells, which were then transfused into the patient for 28 days as a course of treatment. To observe the changes of the proportion of effector cells in patients with CIK cells after transfusion, adverse reactions and the impact on the incidence of infection, hemoglobin and blood transfusion-dependent degree. The results showed that the proportion of CD3 +, CD3 + CD8 +, CD3 + CD56 + cells was significantly increased after CIK cells treatment (p <0.05), and no serious adverse reactions occurred in all patients. CIK cells effectively reduce the incidence of MDS infection and shorten the high fever time. In stable disease, CIK cell infusion can reduce the amount of red blood cells transfused, stabilize hemoglobin level, but can not change the natural course of MDS to high-risk subtypes. Conclusion: Autologous CIK cell infusion is safe and effective in the treatment of MDS in the elderly.